Sanofi
42.85USD
-0.3050 (-0.71%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $1.56▼ | $1.65 | 0 | 1 |
| Next quarter | $1.12▲ | $1.08 | 0 | 1 |
| Current year | $5.02▲ | $4.98 | 5 | 0 |
| Next year | $5.42▲ | $5.29 | 4 | 1 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $1.14 | $1.2 | +0.06 (+5.6%) |
| 2026-03-31 | $1.03 | $1.1 | +0.07 (+7.3%) |
| 2025-12-31 | $0.85 | $0.91 | +0.06 (+7.4%) |
| 2025-09-30 | $1.57 | $1.69 | +0.13 (+8.1%) |
61 ratings from 26 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| UBS | Downgraded from Buy | Neutral | — | Jan 16, 2026 |
| Barclays | Downgraded from Overweight | Equal-Weight | — | Jan 6, 2026 |
| Guggenheim | Downgraded from Buy | Neutral | — | Dec 9, 2025 |
| JP Morgan | Downgraded from Overweight | Neutral | — | Dec 8, 2025 |
| Morgan Stanley | Upgraded from Equal-Weight | Overweight | $56 $58 | Sep 8, 2025 |
| Deutsche Bank | Upgraded from Hold | Buy | — | Sep 2, 2025 |
| JP Morgan | Upgraded from Neutral | Overweight | — | Aug 8, 2025 |
| Goldman Sachs | Initiated | Neutral | $65 | Mar 21, 2025 |
| Argus Research | Maintained | Buy | $55 $60 | Jul 26, 2024 |
| Morgan Stanley | Initiated | Equal-Weight | $55 | Jan 23, 2024 |
| Argus Research | Maintained | Buy | $55 $60 | Mar 27, 2023 |
| Deutsche Bank | Upgraded from Sell | Hold | — | Aug 12, 2022 |
| SVB Leerink | Upgraded from Market Perform | Outperform | — | Sep 27, 2021 |
| Deutsche Bank | Initiated | Sell | — | Jan 15, 2021 |
| Goldman Sachs | Upgraded from Neutral | Buy | — | Mar 11, 2020 |
| Argus Research | Maintained | Buy | $52 $56 | Feb 19, 2020 |
| SVB Leerink | Initiated | Market Perform | — | Feb 11, 2020 |
| JP Morgan | Upgraded from Neutral | Overweight | — | Jan 6, 2020 |
| Barclays | Downgraded from Equal-Weight | Underweight | — | Dec 6, 2019 |
| Guggenheim | Upgraded from Neutral | Buy | — | Sep 23, 2019 |
| Bernstein | Initiated | Outperform | $52 | Sep 3, 2019 |
| Morgan Stanley | Initiated | Equal-Weight | — | Dec 14, 2018 |
| Argus Research | Maintained | Buy | $48 $50 | Nov 8, 2018 |
| Barclays | Upgraded from Underweight | Equal-Weight | — | Nov 1, 2018 |
| B of A Securities | Upgraded from Neutral | Buy | — | Sep 10, 2018 |
No analyst notes on SNY yet.
Analyst Ratings
9 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 4 | 5 | 0 | 0 | Buy2.40 |
| 1 mo ago | 1 | 4 | 5 | 0 | 0 | Buy2.40 |
| 2 mo ago | 0 | 5 | 5 | 0 | 0 | Hold2.50 |
| 3 mo ago | 0 | 5 | 5 | 0 | 0 | Hold2.50 |